Glenmark Pharmaceuticals receives approval for Topiramate capsules

Glenmark Pharmaceuticals Limited, NSE Code:GLENMARK BSE Code: 532296, has received final approval by the United States Food & Drug Administration (U.S. FDA) for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.

Glenmark’s  current  portfolio  consists  of  169  products  authorized  for  distribution  in  the  U.S. marketplace and 43 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.